| pubmed-article:20736812 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20736812 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20736812 | lifeskim:mentions | umls-concept:C0027859 | lld:lifeskim |
| pubmed-article:20736812 | lifeskim:mentions | umls-concept:C0027832 | lld:lifeskim |
| pubmed-article:20736812 | lifeskim:mentions | umls-concept:C0205329 | lld:lifeskim |
| pubmed-article:20736812 | lifeskim:mentions | umls-concept:C1135135 | lld:lifeskim |
| pubmed-article:20736812 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:20736812 | pubmed:dateCreated | 2010-8-25 | lld:pubmed |
| pubmed-article:20736812 | pubmed:abstractText | In vitro treatment of Nf2-deficient cells with epidermal growth factor receptor (EGFR) inhibitors can reduce cellular proliferation. We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2). | lld:pubmed |
| pubmed-article:20736812 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20736812 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20736812 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20736812 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20736812 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20736812 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20736812 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20736812 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20736812 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20736812 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:20736812 | pubmed:issn | 1537-4505 | lld:pubmed |
| pubmed-article:20736812 | pubmed:author | pubmed-author:LoefflerJay... | lld:pubmed |
| pubmed-article:20736812 | pubmed:author | pubmed-author:McKennaMichae... | lld:pubmed |
| pubmed-article:20736812 | pubmed:author | pubmed-author:HalpinChrisC | lld:pubmed |
| pubmed-article:20736812 | pubmed:author | pubmed-author:BarkerFred... | lld:pubmed |
| pubmed-article:20736812 | pubmed:author | pubmed-author:PlotkinScott... | lld:pubmed |
| pubmed-article:20736812 | pubmed:author | pubmed-author:BatchelorTrac... | lld:pubmed |
| pubmed-article:20736812 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20736812 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:20736812 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20736812 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20736812 | pubmed:pagination | 1135-43 | lld:pubmed |
| pubmed-article:20736812 | pubmed:dateRevised | 2011-8-1 | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:meshHeading | pubmed-meshheading:20736812... | lld:pubmed |
| pubmed-article:20736812 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20736812 | pubmed:articleTitle | Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. | lld:pubmed |
| pubmed-article:20736812 | pubmed:affiliation | Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, U.S.A. splotkin@partners.org | lld:pubmed |
| pubmed-article:20736812 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20736812 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:20736812 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
